{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:17:40Z","timestamp":1791821860052,"version":"4.3.4"},"reference-count":95,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012600","name":"ShanghaiTech University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012600","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.bmc.2026.118737","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T23:40:49Z","timestamp":1782776449000},"page":"118737","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Recent advances in Camptothecin-derived antibody-drug conjugates"],"prefix":"10.1016","volume":"141","author":[{"given":"Xianqiang","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingyan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongli","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2026.118737_bb0005","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12943-025-02489-2","article-title":"Antibody-drug conjugates in cancer therapy: current landscape, challenges, and future directions","volume":"24","author":"Chen","year":"2025","journal-title":"Mol Cancer"},{"key":"10.1016\/j.bmc.2026.118737_bb0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004930","article-title":"Beyond the hype: antibody-drug conjugates are advancing faster than our clinical strategy","volume":"23","author":"Notini","year":"2026","journal-title":"PLoS Med"},{"key":"10.1016\/j.bmc.2026.118737_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2025.115648","article-title":"Antibody-drug conjugates as multimodal therapies against hard-to-treat cancers","volume":"224","author":"Armstrong","year":"2025","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.bmc.2026.118737_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpet.2025.103732","article-title":"A review of targeted drug delivery with antibody-drug complexes","volume":"392","author":"Sanjanwala","year":"2025","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bmc.2026.118737_bb0025","doi-asserted-by":"crossref","first-page":"2229101","DOI":"10.1080\/19420862.2023.2229101","article-title":"Exploration of the antibody-drug conjugate clinical landscape","volume":"15","author":"Maecker","year":"2023","journal-title":"MAbs"},{"key":"10.1016\/j.bmc.2026.118737_bb0030","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41571-023-00783-w","article-title":"Optimizing the safety of antibody-drug conjugates for patients with solid tumours","volume":"20","author":"Tarantino","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.bmc.2026.118737_bb0035","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12943-024-01963-7","article-title":"A review of the clinical efficacy of FDA-approved antibody\u2013drug conjugates in human cancers","volume":"23","author":"Liu","year":"2024","journal-title":"Mol Cancer"},{"key":"10.1016\/j.bmc.2026.118737_bb0040","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/s43018-026-01152-z","article-title":"New payloads drive next-gen antibody\u2013drug conjugates","volume":"7","author":"Senior","year":"2026","journal-title":"Nat Cancer"},{"key":"10.1016\/j.bmc.2026.118737_bb0045","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1016\/j.apsb.2023.06.015","article-title":"Antibody-drug conjugates: recent advances in payloads","volume":"13","author":"Wang","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.bmc.2026.118737_bb0050","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13045-022-01397-y","article-title":"Payload diversification: a key step in the development of antibody-drug conjugates","volume":"16","author":"Conilh","year":"2023","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.bmc.2026.118737_bb0055","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.1039\/D5CS01487E","article-title":"Harnessing biosynthetic logic for next-generation ADC payloads","author":"Cai","year":"2026","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.bmc.2026.118737_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116709","article-title":"Antibody-drug conjugates for targeted cancer therapy: recent advances in potential payloads","volume":"276","author":"Xi","year":"2024","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2026.118737_bb0065","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.3390\/molecules30071398","article-title":"Design, Synthesis, and Evaluation of Camptothecin-Based Antibody\u2013Drug Conjugates with High Hydrophilicity and Structural Stability","volume":"30","author":"Xiong","year":"2025","journal-title":"Molecules"},{"key":"10.1016\/j.bmc.2026.118737_bb0070","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1158\/2159-8290.CD-24-0708","article-title":"The Journey of Antibody\u2013Drug Conjugates: Lessons Learned from 40 Years of Development","volume":"14","author":"Colombo","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.bmc.2026.118737_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113639","article-title":"Camptothecin's journey from discovery to WHO essential medicine: fifty years of promise","volume":"223","author":"Khaiwa","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2026.118737_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114304","article-title":"Topoisomerase I inhibitors: challenges, progress and the road ahead","volume":"236","author":"Talukdar","year":"2022","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2026.118737_bb0085","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12032-024-02527-x","article-title":"Camptothecin and its derivatives: advancements, mechanisms and clinical potential in cancer therapy","volume":"41","author":"Kamle","year":"2024","journal-title":"Med Oncol"},{"key":"10.1016\/j.bmc.2026.118737_bb0090","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1021\/acs.jmedchem.3c02115","article-title":"Unleashing the potential of Camptothecin: exploring innovative strategies for structural modification and therapeutic advancements","volume":"67","author":"Chen","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118737_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2021.128146","article-title":"New camptothecin derivatives for generalized oncological chemotherapy: synthesis, stereochemistry and biology","volume":"46","author":"Naumczuk","year":"2021","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2026.118737_bb0100","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.3390\/cancers17061032","article-title":"Camptothein-based anti-Cancer therapies and strategies to improve their therapeutic index","volume":"17","author":"Gong","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.bmc.2026.118737_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104398","article-title":"Irinotecan: 25 years of cancer treatment","volume":"148","author":"Bailly","year":"2019","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.bmc.2026.118737_bb0110","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nrc1977","article-title":"Topoisomerase I inhibitors: camptothecins and beyond","volume":"6","author":"Pommier","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bmc.2026.118737_bb0115","doi-asserted-by":"crossref","first-page":"6581","DOI":"10.1158\/1078-0432.CCR-19-1089","article-title":"Targeting topoisomerase I in the era of precision medicine","volume":"25","author":"Thomas","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bmc.2026.118737_bb0120","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1021\/acs.bioconjchem.5b00223","article-title":"Sacituzumab Govitecan (IMMU-132), an anti-Trop-2\/SN-38 antibody-drug conjugate: characterization and efficacy in pancreatic, gastric, and other cancers","volume":"26","author":"Cardillo","year":"2015","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.bmc.2026.118737_bb0125","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.annonc.2019.11.019","article-title":"The art of innovation: clinical development of trastuzumab deruxtecan and redefining how antibody-drug conjugates target HER2-positive cancers","volume":"31","author":"Yver","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bmc.2026.118737_bb0130","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1146\/annurev-med-071322-065903","article-title":"Leveraging TROP2 antibody-drug conjugates in solid Tumors","volume":"75","author":"Nelson","year":"2024","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.bmc.2026.118737_bb0135","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3390\/ph14030247","article-title":"Exatecan antibody drug conjugates based on a hydrophilic Polysarcosine drug-linker platform","volume":"14","author":"Conilh","year":"2021","journal-title":"Pharmaceuticals-Base"},{"key":"10.1016\/j.bmc.2026.118737_bb0140","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1158\/1535-7163.MCT-21-0206","article-title":"Datopotamab Deruxtecan, a novel TROP2-directed antibody-drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells","volume":"20","author":"Okajima","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bmc.2026.118737_bb0145","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1158\/1535-7163.MCT-21-0554","article-title":"DS-7300a, a DNA topoisomerase I inhibitor, DXd-based antibody-drug conjugate targeting B7-H3, exerts potent antitumor activities in preclinical models","volume":"21","author":"Yamato","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bmc.2026.118737_bb0150","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1158\/1535-7163.MCT-23-0198","article-title":"AMT-562, a novel HER3-targeting antibody-drug conjugate, demonstrates a potential to broaden therapeutic opportunities for HER3-expressing Tumors","volume":"22","author":"Weng","year":"2023","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bmc.2026.118737_bb0155","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1158\/1535-7163.MCT-23-0822","article-title":"Design and evaluation of ZD06519, a novel Camptothecin payload for antibody drug conjugates","volume":"23","author":"Petersen","year":"2024","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bmc.2026.118737_bb0160","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1158\/1535-7163.MCT-23-0359","article-title":"Design and evaluation of Phosphonamidate-linked Exatecan constructs for highly loaded, stable, and efficacious antibody-drug conjugates","volume":"23","author":"Schmitt","year":"2024","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bmc.2026.118737_bb0165","doi-asserted-by":"crossref","first-page":"19852","DOI":"10.1021\/acs.jmedchem.4c02243","article-title":"Evaluation of double self-Immolative linker-based antibody-drug conjugate FDA022-BB05 with enhanced therapeutic potential","volume":"67","author":"Zhang","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118737_bb0170","doi-asserted-by":"crossref","first-page":"19122","DOI":"10.1021\/acs.jmedchem.5c01184","article-title":"Development of optimized Exatecan-based immunoconjugates with potent antitumor efficacy in HER2-positive breast Cancer","volume":"68","author":"Auvert","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118737_bb0175","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1158\/1535-7163.MCT-24-0588","article-title":"OBI-992, a novel TROP2-targeted antibody-drug conjugate, demonstrates antitumor activity in multiple Cancer models","volume":"24","author":"Li","year":"2025","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bmc.2026.118737_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117305","article-title":"Exploiting synthetic lethality in PDAC with antibody drug conjugates and ATR inhibition","volume":"286","author":"Li","year":"2025","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2026.118737_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117877","article-title":"Deuterium substitution at the intolerable site as a strategy to mitigate the toxicity of camptothecin derivatives","volume":"296","author":"Yu","year":"2025","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2026.118737_bb0190","first-page":"413","article-title":"Discovery and preclinical evaluation of PBX-7016, a methylenedioxy-camptothecin payload for antibody-drug conjugates with enhanced therapeutic potential","volume":"69","author":"Chun","year":"2026","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118737_bb0195","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab Deruxtecan in previously treated HER2-positive breast Cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmc.2026.118737_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111682","article-title":"Novel HER2-targeting antibody-drug conjugates of trastuzumab beyond T-DM1 in breast Cancer: trastuzumab Deruxtecan(DS-8201a) and (Vic-)trastuzumab Duocarmazine (SYD985)","volume":"183","author":"Xu","year":"2019","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2026.118737_bb0205","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bmc.2026.118737_bb0210","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1248\/cpb.c18-00744","article-title":"The latest Research and Development into the antibody-drug conjugate, [fam-] trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer therapy","volume":"67","author":"Nakada","year":"2019","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"10.1016\/j.bmc.2026.118737_bb0215","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.1002\/cncr.30789","article-title":"Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: safety and pharmacokinetics","volume":"123","author":"Ocean","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.bmc.2026.118737_bb0220","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1158\/1078-0432.CCR-10-2939","article-title":"Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys","volume":"17","author":"Cardillo","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bmc.2026.118737_bb0225","doi-asserted-by":"crossref","first-page":"5131","DOI":"10.1158\/1078-0432.CCR-15-0670","article-title":"Enhanced delivery of SN-38 to human tumor xenografts with an anti-Trop-2-SN-38 antibody conjugate (Sacituzumab Govitecan)","volume":"21","author":"Sharkey","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bmc.2026.118737_bb0230","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1158\/1078-0432.CCR-14-3321","article-title":"First-in-human trial of a novel anti-Trop-2 antibody-SN-38 conjugate, Sacituzumab Govitecan, for the treatment of diverse metastatic solid Tumors","volume":"21","author":"Starodub","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bmc.2026.118737_bb0235","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1097\/MS9.0000000000003122","article-title":"FDA approves Datroway: a novel therapy for HR-positive, HER2-negative metastatic breast cancer","volume":"87","author":"Sibomana","year":"2025","journal-title":"Ann Med Surg"},{"key":"10.1016\/j.bmc.2026.118737_bb0240","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1177\/10600280251393259","article-title":"Targeting TROP2 across solid Tumors: the clinical profile and role of Datopotamab Deruxtecan","volume":"60","author":"Lucky","year":"2025","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.bmc.2026.118737_bb0245","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.951589","article-title":"Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132","volume":"12","author":"Cheng","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.bmc.2026.118737_bb0250","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.ejmech.2013.01.058","article-title":"Evolution in medicinal chemistry of E-ring-modified Camptothecin analogs as anticancer agents","volume":"63","author":"Huang","year":"2013","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2026.118737_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116899","article-title":"Synthesis and evaluation of homocamptothecin antibody-drug conjugates for cancer treatment","volume":"279","author":"Li","year":"2024","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2026.118737_bb0260","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12943-015-0362-9","article-title":"FL118, a novel camptothecin derivative, is insensitive to ABCG2 expression and shows improved efficacy in comparison with irinotecan in colon and lung cancer models with ABCG2-induced resistance","volume":"14","author":"Westover","year":"2015","journal-title":"Mol Cancer"},{"key":"10.1016\/j.bmc.2026.118737_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2024.130085","article-title":"Design, synthesis and biological evaluation of camptothecin analogue FL118 as a payload for antibody-drug conjugates in targeted cancer therapy","volume":"118","author":"Mathi","year":"2025","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2026.118737_bb0270","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.bmcl.2016.02.020","article-title":"Novel antibody drug conjugates containing exatecan derivative-based cytotoxic payloads","volume":"26","author":"Nakada","year":"2016","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2026.118737_bb0275","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1021\/acs.jmedchem.5c03548","article-title":"Valine-alanine-based peptidomimetic linker for antibody-drug conjugates","volume":"69","author":"Li","year":"2026","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118737_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2026.114873","article-title":"\u03b2-Glucuronidase-triggered ortho-hydroxyl-mediated cyclization strategy for the efficient delivery of phenolic payloads in antibody-drug conjugates","volume":"394","author":"Chen","year":"2026","journal-title":"J Control Release"},{"key":"10.1016\/j.bmc.2026.118737_bb0285","doi-asserted-by":"crossref","first-page":"18099","DOI":"10.1021\/acs.jmedchem.5c01500","article-title":"Recent advances in peptide linkers of antibody-drug conjugates","volume":"68","author":"Yang","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118737_bb0290","doi-asserted-by":"crossref","first-page":"396","DOI":"10.3390\/pharmaceutics14020396","article-title":"Linkers: an Assurance for Controlled Delivery of antibody-drug conjugate","volume":"14","author":"Sheyi","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bmc.2026.118737_bb0295","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1002\/med.21720","article-title":"Making smart drugs smarter: the importance of linker chemistry in targeted drug delivery","volume":"40","author":"Yang","year":"2020","journal-title":"Med Res Rev"},{"key":"10.1016\/j.bmc.2026.118737_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2026.114612","article-title":"The role of hydrophilic linkers in next-generation antibody-drug conjugates","volume":"391","author":"Fu","year":"2026","journal-title":"J Control Release"},{"key":"10.1016\/j.bmc.2026.118737_bb0305","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1021\/acs.bioconjchem.6c00056","article-title":"Linker chemistry in radiopharmaceutical design","volume":"37","author":"Stoddard","year":"2026","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.bmc.2026.118737_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.biotechadv.2026.108841","article-title":"Multivalent linkers: a growing trend in antibody-drug conjugate development","volume":"89","author":"Gulyak","year":"2026","journal-title":"Biotechnol Adv"},{"key":"10.1016\/j.bmc.2026.118737_bb0315","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1016\/j.apsb.2021.03.042","article-title":"Antibody-drug conjugates: recent advances in linker chemistry","volume":"11","author":"Su","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.bmc.2026.118737_bb0320","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jconrel.2024.01.012","article-title":"Branched pegylated linker-auristatin to control hydrophobicity for the production of homogeneous minibody-drug conjugate against HER2-positive breast cancer","volume":"366","author":"Douez","year":"2024","journal-title":"J Control Release"},{"key":"10.1016\/j.bmc.2026.118737_bb0325","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jconrel.2021.07.041","article-title":"Polyethylene glycol-based linkers as hydrophilicity reservoir for antibody-drug conjugates","volume":"337","author":"Tedeschini","year":"2021","journal-title":"J Control Release"},{"key":"10.1016\/j.bmc.2026.118737_bb0330","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1039\/C9SC00285E","article-title":"Monodisperse polysarcosine-based highly-loaded antibody-drug conjugates","volume":"10","author":"Viricel","year":"2019","journal-title":"Chem Sci"},{"key":"10.1016\/j.bmc.2026.118737_bb0335","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1021\/jm2002958","article-title":"Synthesis and evaluation of hydrophilic linkers for antibody-maytansinoid conjugates","volume":"54","author":"Zhao","year":"2011","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118737_bb0340","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1021\/ml100039h","article-title":"Expanded utility of the \u03b2-glucuronide linker: ADCs that deliver phenolic cytotoxic agents","volume":"1","author":"Jeffrey","year":"2010","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmc.2026.118737_bb0345","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1021\/bc0600214","article-title":"Development and properties of beta-glucuronide linkers for monoclonal antibody-drug conjugates","volume":"17","author":"Jeffrey","year":"2006","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.bmc.2026.118737_bb0350","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1177\/10915818241306039","article-title":"The nonclinical safety assessment of a novel anti-CEACAM5 antibody exatecan conjugate predicts a low risk for interstitial lung disease (ILD) in patients-the putative mechanism behind ILD","volume":"44","author":"Sloot","year":"2025","journal-title":"Int J Toxicol"},{"key":"10.1016\/j.bmc.2026.118737_bb0355","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1021\/acs.bioconjchem.3c00363","article-title":"Generation and characterization of Iduronidase-cleavable ADCs","volume":"34","author":"J\u00e4ger","year":"2023","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.bmc.2026.118737_bb0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2020.114932","article-title":"Reducing the antigen-independent toxicity of antibody-drug conjugates by minimizing their non-specific clearance through PEGylation","volume":"392","author":"Simmons","year":"2020","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.bmc.2026.118737_bb0365","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s41392-020-00247-y","article-title":"Construction of paclitaxel-based antibody-drug conjugates with a PEGylated linker to achieve superior therapeutic index","volume":"5","author":"Shao","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.bmc.2026.118737_bb0370","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.bmcl.2018.03.005","article-title":"Site-specific and hydrophilic ADCs through disulfide-bridged linker and branched PEG","volume":"28","author":"Shao","year":"2018","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2026.118737_bb0375","doi-asserted-by":"crossref","first-page":"6949","DOI":"10.1021\/jm500766w","article-title":"Ado-trastuzumab emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer","volume":"57","author":"Lambert","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118737_bb0380","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.3390\/ijms20051115","article-title":"HER2 directed antibody-drug-conjugates beyond T-DM1 in breast Cancer","volume":"20","author":"Rinnerthaler","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmc.2026.118737_bb0385","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1158\/2159-8290.CD-22-1368","article-title":"Antibody-Exatecan conjugates with a novel self-immolative moiety overcome resistance in Colon and Lung Cancer","volume":"13","author":"Weng","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.bmc.2026.118737_bb0390","doi-asserted-by":"crossref","first-page":"7948","DOI":"10.1002\/anie.201601506","article-title":"The methylene alkoxy carbamate self-Immolative unit: utilization for the targeted delivery of alcohol-containing payloads with antibody-drug conjugates","volume":"55","author":"Kolakowski","year":"2016","journal-title":"Angew Chem Int Ed"},{"key":"10.1016\/j.bmc.2026.118737_bb0395","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0292871","article-title":"Synthesis and biological evaluation of novel quaternary ammonium antibody drug conjugates based on camptothecin derivatives","volume":"18","author":"Zhang","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.bmc.2026.118737_bb0400","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1158\/1535-7163.MCT-16-0038","article-title":"Development of novel quaternary ammonium linkers for antibody-drug conjugates","volume":"15","author":"Burke","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bmc.2026.118737_bb0405","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.apsb.2024.12.036","article-title":"Resistance to antibody-drug conjugates: a review","volume":"15","author":"Li","year":"2025","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.bmc.2026.118737_bb0410","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1158\/1078-0432.CCR-24-2771","article-title":"TOP1 mutations and cross-resistance to antibody-drug conjugates in patients with metastatic breast Cancer","volume":"31","author":"Abelman","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bmc.2026.118737_bb0415","doi-asserted-by":"crossref","first-page":"7233","DOI":"10.3390\/ijms24087233","article-title":"Resistance to TOP-1 inhibitors: good old drugs still can surprise us","volume":"24","author":"Kumar","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmc.2026.118737_bb0420","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.105015","article-title":"Antibody-drug conjugates in oncology: a spotlight on overcoming resistance","volume":"217","author":"Xu","year":"2026","journal-title":"Crit Rev Oncol Hemat"},{"key":"10.1016\/j.bmc.2026.118737_bb0425","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202515498","article-title":"Understanding and overcoming antibody-drug conjugate resistance: biological mechanisms and emerging analytical frameworks in breast cancer","volume":"13","author":"Seo","year":"2026","journal-title":"Adv Sci"},{"key":"10.1016\/j.bmc.2026.118737_bb0430","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13045-025-01752-9","article-title":"Overcoming resistance to antibody-drug conjugates: from mechanistic insights to cutting-edge strategies","volume":"18","author":"Zhou","year":"2025","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.bmc.2026.118737_bb0435","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1158\/1535-7163.MCT-21-1000","article-title":"TOP1-DNA trapping by Exatecan and combination therapy with ATR inhibitor","volume":"21","author":"Jo","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bmc.2026.118737_bb0440","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/jamaoncol.2023.4025","article-title":"Berzosertib plus topotecan vs topotecan alone in patients with relapsed small cell lung Cancer: a randomized clinical trial","volume":"9","author":"Takahashi","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.bmc.2026.118737_bb0445","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1158\/1078-0432.CCR-23-0536","article-title":"Targeting replication stress and chemotherapy resistance with a combination of Sacituzumab Govitecan and Berzosertib: a phase I clinical trial","volume":"29","author":"Abel","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bmc.2026.118737_bb0450","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","article-title":"Exploring the next generation of antibody-drug conjugates","volume":"21","author":"Tsuchikama","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.bmc.2026.118737_bb0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116995","article-title":"Dual-payload antibody-drug conjugates: taking a dual shot","volume":"281","author":"Tao","year":"2025","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2026.118737_bb0460","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/d41573-025-00121-y","article-title":"Dual-payload ADCs move into first oncology clinical trials","volume":"24","author":"Mullard","year":"2025","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmc.2026.118737_bb0465","doi-asserted-by":"crossref","first-page":"2498162","DOI":"10.1080\/19420862.2025.2498162","article-title":"Homogeneous antibody-drug conjugates with dual payloads: potential, methods and considerations","volume":"17","author":"Wen","year":"2025","journal-title":"MAbs"},{"key":"10.1016\/j.bmc.2026.118737_bb0470","doi-asserted-by":"crossref","first-page":"967","DOI":"10.3390\/pharmaceutics17080967","article-title":"A dual-payload bispecific ADC improved potency and efficacy over single-payload bispecific ADCs","volume":"17","author":"Wilski","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bmc.2026.118737_bb0475","doi-asserted-by":"crossref","first-page":"S451","DOI":"10.1016\/j.annonc.2025.08.1073","article-title":"653eTiP translational study and first-in-human (FIH) study design of KH815, a novel dual-payload TROP-2 targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors","volume":"36","author":"Ma","year":"2025","journal-title":"Ann Oncol"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089626001938?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089626001938?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T11:21:37Z","timestamp":1786015297000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089626001938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":95,"alternative-id":["S0968089626001938"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118737","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent advances in Camptothecin-derived antibody-drug conjugates","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118737","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118737"}}